<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04639414</url>
  </required_header>
  <id_info>
    <org_study_id>Combat_T2_NASH_002</org_study_id>
    <secondary_id>2019-001987-31</secondary_id>
    <nct_id>NCT04639414</nct_id>
  </id_info>
  <brief_title>Combined Active Treatment in Type 2 Diabetes With NASH</brief_title>
  <acronym>COMBAT_T2_NASH</acronym>
  <official_title>Combined Active Treatment in Type 2 Diabetes With NASH</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Deutsche Diabetes Forschungsgesellschaft e.V.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>German Center for Diabetes Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Federal Ministry of Health, Germany</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ministry of Innovation, Science and Research in North Rhine-Westphalia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>German Diabetes Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this multicentre, prospective, placebo-controlled, double-blind, randomized, 3-arm&#xD;
      parallel group, interventional study is to assess for the first time the effects of either a&#xD;
      combined therapy with the antihyperglycemic drugs semaglutide and empagliflozin or&#xD;
      empagliflozin monotherapy compared to placebo as potential treatments for non-alcoholic&#xD;
      steatohepatitis (NASH) in patients with type 2 diabetes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Obesity and type 2 diabetes (T2D) are tightly associated with non-alcoholic fatty liver&#xD;
      disease (NAFLD), which in turn predicts the development of T2D and cardiovascular disease.&#xD;
&#xD;
      Up to 80% of NAFLD patients with T2D have NASH and the presence of T2D is an independent risk&#xD;
      factor for more-advanced fibrosis, higher rate of fibrosis progression, and increased&#xD;
      mortality. Liver-related mortality is increased 10-fold in NASH patients compared with the&#xD;
      general population. In addition, people with NASH are at an excessive risk of cardiovascular&#xD;
      morbidity and mortality.&#xD;
&#xD;
      Currently, there are no established pharmacotherapies for NASH patients with T2D.&#xD;
&#xD;
      The aim of this trial is to evaluate efficacy of a combined treatment with semaglutide 1&#xD;
      mg/week (GLP1RA) and empagliflozin 10 mg/d (SGLT2I) or ii) empagliflozin 10 mg/d monotherapy&#xD;
      by means of histological resolution of NASH in T2D patients without progression of fibrosis&#xD;
      after 48 weeks treatment.&#xD;
&#xD;
      To confirm a histological diagnosis of NASH and proof efficacy of treatment, a liver biopsy&#xD;
      will be performed prior to screening as well as at the end of treatment phase.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 26, 2021</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
    <masking_description>double-blind placebo-controlled</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Histological resolution of NASH without worsening of fibrosis</measure>
    <time_frame>from baseline to 48 weeks</time_frame>
    <description>NAFLD status will be assessed by histologic evaluation of liver biopsy samples based on NAFLD activity score. NASH resolution is defined by disappearance of ballooning (score 0), together with either disappearance of lobular inflammation or the persistence of mild lobular inflammation only (score 0 or 1) and resulting in an overall pathologic diagnosis of either steatosis alone or steatosis with mild inflammation; with no worsening of fibrosis. Worsening of fibrosis is defined by an increase of at least one stage of the Kleiner fibrosis classification.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall NAFLD activity score (NAS)</measure>
    <time_frame>from baseline to 48 weeks</time_frame>
    <description>Sum of a) steatosis (0-3 points), b) lobular inflammation (scored 0-3 points), c) hepatocellular ballooning (scored 0-2 points) assessed by liver histology</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stage of fibrosis according to the Kleiner Fibrosis Classification</measure>
    <time_frame>from baseline to 48 weeks</time_frame>
    <description>Assessed by liver histology according to the Kleiner Fibrosis Classification (stages 0-4)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Activity component of NASH according to the steatosis-activity-fibrosis (SAF) score</measure>
    <time_frame>from baseline to 48 weeks</time_frame>
    <description>Sum of lobular inflammation (scored 0-3 points)and hepatocellular ballooning (scored 0-2 points) assessed by liver histology</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hepatic steatosis grade</measure>
    <time_frame>from baseline to 48 weeks</time_frame>
    <description>steatosis grade (0-3) assessed by liver histology</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">192</enrollment>
  <condition>Type 2 Diabetes</condition>
  <condition>Non-alcoholic Steatohepatitis (NASH)</condition>
  <condition>Non-alcoholic Fatty Liver Disease (NAFLD)</condition>
  <arm_group>
    <arm_group_label>Combined treatment with Empagliflozin and Semaglutide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combined treatment with Empagliflozin, film-coated tablet, 10mg once daily and Semaglutide, colourless solution in pre-filled pen, 1mg once weekly</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Empagliflozin monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Empagliflozin, film-coated tablet, 10mg once daily and Placebo matching Semaglutide (colourless solution in pre-filled pen, once weekly)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo matching Empagliflozin (film-coated tablet, once daily) and Placebo matching Semaglutide (colourless solution in pre-filled pen, once weekly)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Empagliflozin 10mg oral tablet / Semaglutide 1mg pen injector</intervention_name>
    <description>Measurement of the effect of the combined treatment with semaglutide 1mg/week and empagliflozin 10 mg/d compared to matching placebo after 48-week treatment.</description>
    <arm_group_label>Combined treatment with Empagliflozin and Semaglutide</arm_group_label>
    <other_name>Jardiance(R), Ozempic(R)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Empagliflozin 10mg oral tablet and placebo pen injector matching semaglutide</intervention_name>
    <description>Measurement of the effect of empagliflozin monotherapy 10mg/d compared to matching placebo after 48-week treatment.</description>
    <arm_group_label>Empagliflozin monotherapy</arm_group_label>
    <other_name>Jardiance(R)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo matching empagliflozin and placebo pen injector matching semaglutide</intervention_name>
    <description>Measurement of the effect of the combined treatment with semaglutide 1mg/week and empagliflozin 10 mg/d OR empagliflozin monotherapy 10mg/d compared to matching placebo after 48-week treatment.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Control / Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of T2D and NASH with fibrosis stage F1-F3&#xD;
&#xD;
          -  Age between 25 and 75 years&#xD;
&#xD;
          -  HbA1c ≤ 9.5%&#xD;
&#xD;
          -  BMI ≤ 45 kg/m2&#xD;
&#xD;
          -  obtained written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Contraindications on liver biopsy&#xD;
&#xD;
          -  Evidence of cirrhosis on liver biopsy&#xD;
&#xD;
          -  Liver disease of other etiology including chronic viral hepatitis (B or C), alcohol&#xD;
             abuse, hemochromatosis, alpha-1 antitrypsin deficiency, autoimmune hepatitis, Wilson's&#xD;
             disease, primary sclerosing cholangitis or primary biliary cirrhosis, or liver&#xD;
             cirrhosis of any etiology&#xD;
&#xD;
          -  History of diabetic ketoacidosis&#xD;
&#xD;
          -  Current treatment with immunomodulatory drugs (oral/intravenous steroids on &gt; 7&#xD;
             consecutive days, methotrexate, amiodarone, biologicals)&#xD;
&#xD;
          -  Alcohol consumption &gt;30 g/d for males and &gt;20 g/d for females&#xD;
&#xD;
          -  Past (≥5 years) or current history of alcohol or drug abuse and/or psychiatric disease&#xD;
             including severe depression necessitating pharmacological treatment&#xD;
&#xD;
          -  Medications that induce steatosis: estrogen or other hormonal replacement therapy&#xD;
             (except oral contraception), tamoxifen, raloxifene, oral glucocorticoids or&#xD;
             chloroquine&#xD;
&#xD;
          -  Planned pregnancy, pregnant or lactating women, positive pregnancy test, and woman of&#xD;
             childbearing potential not using two adequate methods of contraception, including a&#xD;
             barrier method and a highly efficacious non-barrier method&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Roden, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Deutsches Diabetes-Zentrum</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sabine Kahl, MD</last_name>
    <phone>+4921133820</phone>
    <email>sabine.kahl@ddz.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alexandra Müller, PhD</last_name>
    <phone>+4921133820</phone>
    <email>alexandra.mueller@ddz.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>German Diabetes Center</name>
      <address>
        <city>Duesseldorf</city>
        <state>Nordrhein-Westfalen</state>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+49/2113382740</phone>
      <email>sabine.kahl@ddz.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Franziskus-Krankenhaus Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>10787</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Clinics Berlin Charité</name>
      <address>
        <city>Berlin</city>
        <zip>12200</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Clinics Berlin Charité</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Clinics Bochum</name>
      <address>
        <city>Bochum</city>
        <zip>44892</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Städtisches Klinikum Braunschweig gGmbH</name>
      <address>
        <city>Braunschweig</city>
        <zip>38126</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Clinics Carl Gustav Carus Dresden</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Clinics Essen</name>
      <address>
        <city>Essen</city>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>St.Josef-Krankenhaus Kupferdreh</name>
      <address>
        <city>Essen</city>
        <zip>45257</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Clinics Frankfurt</name>
      <address>
        <city>Frankfurt</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Clinics Freiburg</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Diabetes-Zentrum Gelnhausen</name>
      <address>
        <city>Gelnhausen</city>
        <zip>63571</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Clinics Greifswald</name>
      <address>
        <city>Greifswald</city>
        <zip>17475</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Clinics Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Eugastro GmbH</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Clinics Leipzig</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Clinics Johannes-Gutenberg Mainz</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Clinics Munich LMU</name>
      <address>
        <city>Munich</city>
        <zip>80336</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Clinics Münster</name>
      <address>
        <city>Münster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Clinics Tübingen</name>
      <address>
        <city>Tübingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Clinics Ulm</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Clinics Würzburg</name>
      <address>
        <city>Würzburg</city>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>April 5, 2019</study_first_submitted>
  <study_first_submitted_qc>November 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 20, 2020</study_first_posted>
  <last_update_submitted>May 25, 2021</last_update_submitted>
  <last_update_submitted_qc>May 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Type 2 Diabetes</keyword>
  <keyword>Non-alcoholic Steatohepatitis (NASH)</keyword>
  <keyword>Non-alcoholic Fatty Liver Disease (NAFLD)</keyword>
  <keyword>Fatty liver</keyword>
  <keyword>Diabetes mellitus</keyword>
  <keyword>Empagliflozin</keyword>
  <keyword>Semaglutide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Empagliflozin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

